These genetic variants were all confirmed in the tumor area deficient in MLH1/PMS2 protein expression (A2), which confirmed a shared tumor origin; however, this region exhibited a significantly higher tumor burden, indicating its further molecular evolution. The gene discussed is PMS2; the disease is neoplasm.